Enterococcus Species and Resistance

Enterococci are not just harmless gut bacteria; they are master opportunists, responsible for some of the most challenging and drug-resistant infections in modern hospitals. Understanding their unique biology and formidable resistance mechanisms is critical for any future clinician, as these pathogens demand a specific diagnostic and therapeutic approach distinct from other common gram-positive cocci.

From Commensal to Pathogen: The Microbiology of Enterococci

Enterococci are gram-positive, facultatively anaerobic cocci that typically occur in pairs or short chains. They are hardy organisms, capable of surviving in harsh environments, including those with high salt concentrations and bile salts. This resilience is a key reason they are such successful pathogens. As part of the normal gastrointestinal (GI) flora, they live as commensals, contributing to a balanced microbial ecosystem. However, when the body's defenses are breached—often due to medical interventions—these microbes can invade and cause significant disease.

The two most clinically significant species are Enterococcus faecalis and Enterococcus faecium. While E. faecalis is more common overall, E. faecium is notably associated with a higher incidence of multidrug resistance, particularly in hospital settings. A crucial initial identification point is that enterococci are intrinsically resistant to several common antibiotic classes. This means the resistance is a natural, chromosomally encoded characteristic of the genus, not one acquired through mutation or gene transfer. Most notably, they are resistant to all cephalosporins and have low-level intrinsic resistance to aminoglycosides, which is why these drugs are never used as monotherapy for enterococcal infections.

Pathogenesis and Key Clinical Syndromes

Enterococci cause disease primarily in patients whose host defenses are compromised. They are classic nosocomial (hospital-acquired) pathogens, often spreading via the hands of healthcare workers or on contaminated medical equipment. Their ability to form biofilms on devices like urinary catheters and central venous lines further facilitates infection. The three major clinical syndromes you must associate with enterococci are urinary tract infections, endocarditis, and intra-abdominal infections.

Urinary tract infections (UTIs) are the most common presentation, frequently occurring in hospitalized patients with indwelling urinary catheters. The bacteria ascend from the perineum, which is colonized with gut flora, into the urinary tract. Endocarditis is a severe, life-threatening infection of the heart valves. Enterococci typically cause subacute endocarditis, often in older men with underlying valvular disease or following genitourinary procedures. Finally, intra-abdominal infections such as peritonitis and abscesses can occur when enterococci escape the GI tract, for example, after bowel surgery, trauma, or perforation. Here, they are often part of a polymicrobial infection.

The Spectrum of Antimicrobial Resistance

Enterococcal resistance is a two-tiered problem: intrinsic and acquired. As mentioned, intrinsic resistance to cephalosporins and low-level aminoglycoside resistance is a fundamental trait. The clinical impact of low-level aminoglycoside resistance is overcome by using a combination therapy: a cell-wall active agent (like a penicillin or vancomycin) plus a high-dose aminoglycoside (like gentamicin). This combination creates a synergistic bactericidal effect, which is essential for treating serious infections like endocarditis.

The greater challenge is acquired resistance. The most formidable of these is vancomycin-resistant enterococci (VRE). Resistance is mediated by the acquisition of gene clusters, most commonly vanA or vanB. These genes alter the bacterial cell wall target (replacing D-alanine-D-alanine with D-alanine-D-lactate), to which vancomycin can no longer bind effectively. The vanA genotype confers high-level resistance to both vancomycin and teicoplanin, while vanB typically confers resistance to vancomycin only. VRE strains, particularly E. faecium, are a major concern in intensive care units and among immunocompromised patients, as treatment options become severely limited.

Clinical Management and Treatment Strategies

Treating enterococcal infections requires careful selection based on the infection site, severity, and resistance profile. For simple UTIs caused by vancomycin-susceptible strains, ampicillin or amoxicillin may be sufficient. For serious infections like endocarditis or meningitis, combination synergistic therapy (ampicillin or vancomycin + gentamicin) is the cornerstone for achieving a bactericidal effect.

When faced with VRE, you must pivot to alternative agents. Linezolid, an oxazolidinone antibiotic that inhibits protein synthesis, is a reliable oral and intravenous option for VRE infections. However, myelosuppression (anemia, thrombocytopenia) with prolonged use is a significant side effect that requires monitoring. Daptomycin, a lipopeptide that disrupts bacterial cell membrane function, is a potent bactericidal option, especially for bloodstream infections and endocarditis. Its efficacy can be reduced in pulmonary infections, so it is not recommended for pneumonia. Other options include tigecycline (for intra-abdominal infections) and the newer combination agent ceftaroline-avibactam, which has activity against certain VRE strains.

Common Pitfalls

1. Assuming Susceptibility to Common Drugs: A major error is empirically treating a suspected gram-positive infection with a cephalosporin (e.g., ceftriaxone) without considering enterococci. Given their intrinsic resistance, this therapy will fail. Always consider the possibility of enterococcus in healthcare-associated infections.
2. Monotherapy for Serious Infections: Using a single agent (even an active one like ampicillin) for endocarditis is a mistake. Without the addition of an aminoglycoside for synergy, the treatment is merely bacteriostatic, leading to high relapse rates. Combination therapy is mandatory for cure.
3. Misinterpreting the "VRE" Label: Not all VRE infections require the same aggressive therapy. A VRE-positive urine culture in an asymptomatic catheterized patient may only require catheter change or removal, not antibiotics. Reserve treatment for true symptomatic infections to reduce selection pressure for further resistance.
4. Overlooking Source Control: In infections like intra-abdominal abscesses or catheter-associated bacteremia, antibiotics alone are insufficient. Failing to drain an abscess or remove an infected central line will almost certainly lead to treatment failure, regardless of how appropriate the antibiotic choice is.

Summary

• Enterococci (E. faecalis and E. faecium) are hardy, gram-positive cocci that are normal inhabitants of the GI tract but cause nosocomial infections like UTIs, endocarditis, and intra-abdominal abscesses in compromised hosts.
• They possess intrinsic resistance to all cephalosporins and exhibit low-level resistance to aminoglycosides, making standard gram-positive therapy ineffective.
• Vancomycin-resistant enterococci (VRE), acquired via vanA or vanB genes, represent a major public health threat, severely limiting treatment options in hospitals.
• Treatment for serious infections requires combination therapy (e.g., ampicillin + gentamicin) for synergy. VRE infections are treated with alternative agents like linezolid or daptomycin.
• Successful management always combines correct antibiotic selection with essential clinical actions like removing infected devices and draining abscesses.